Abstract

The repeat region of the Plasmodium falciparum circumsporozoite protein (CSP) is a major vaccine antigen because it can be targeted by parasite neutralizing antibodies; however, little is known about this interaction. We used isothermal titration calorimetry, X-ray crystallography and mutagenesis-validated modeling to analyze the binding of a murine neutralizing antibody to Plasmodium falciparum CSP. Strikingly, we found that the repeat region of CSP is bound by multiple antibodies. This repeating pattern allows multiple weak interactions of single FAB domains to accumulate and yield a complex with a dissociation constant in the low nM range. Because the CSP protein can potentially cross-link multiple B cell receptors (BCRs) we hypothesized that the B cell response might be T cell independent. However, while there was a modest response in mice deficient in T cell help, the bulk of the response was T cell dependent. By sequencing the BCRs of CSP-repeat specific B cells in inbred mice we found that these cells underwent somatic hypermutation and affinity maturation indicative of a T-dependent response. Last, we found that the BCR repertoire of responding B cells was limited suggesting that the structural simplicity of the repeat may limit the breadth of the immune response.

Highlights

  • Malaria caused by Plasmodium falciparum causes the deaths of around 430,000 people each year [1]

  • In the case of malaria, our most advanced vaccine candidates aim to promote the production of antibodies that recognize the circumsporozoite protein (CSP) molecule on the surface of the invasive parasite stage called the sporozoite

  • Antibody responses to the Plasmodium circumsporozoite protein had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript

Read more

Summary

Introduction

Malaria caused by Plasmodium falciparum causes the deaths of around 430,000 people each year [1]. Phase II and Phase III clinical trials have repeatedly demonstrated that the vaccine gives around 50% protection against clinical malaria in field settings for the first year following vaccination [3]. The bulk of protection is attributed to antibodies targeting the CSP repeat epitope included within the vaccine, with some contribution from CD4+ T cells [4]. It is still unclear why the antibody response to CSP is only partially protective. We lack structural information about how neutralizing antibodies bind to CSP and knowledge on the breadth and nature of the B cell response elicited

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call